Literature DB >> 9259929

Isolated ductal closure in utero diagnosed by fetal echocardiography.

S D Leal1, T Cavallé-Garrido, G Ryan, D Farine, M Heilbut, J F Smallhorn.   

Abstract

In utero isolated ductal closure is uncommon and can lead to fetal hydrops and death if not recognized. Five fetuses were diagnosed prenatally by echocardiography. The reasons for referral were hydrops (2), cardiomegaly (1), polyhydramnios and choroid plexus cyst (1), and polyhydramnios and teratoma of the neck (1). Gestational age was median 32, range 18-41 weeks. Two mothers received indomethacin for polyhydramnios, with the echocardiogram performed 5 and 3 days after the last dose. Three had a negative history of drug ingestion. Fetal echocardiograms showed absent flow in the ductus arteriosus, dilated right ventricle with decreased function, and mild or moderate tricuspid and pulmonary insufficiency in all. The left ventricle was hypercontractile, with significantly increased left ventricular stroke output when compared to the right. Four fetuses were delivered by cesarean section and had an uneventful course. One fetus died shortly after birth due to airway obstruction from a large teratoma. Autopsy showed ductal constriction. Postnatal echocardiograms showed absent ductal flow and dilated right ventricle. On follow-up, survivors remained asymptomatic with cardiac size returning to normal. Premature closure of the ductus arteriosus should be considered in hydrops of unknown etiology, right ventricular dysfunction, and following indomethacin therapy. Urgent delivery results in an excellent prognosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9259929     DOI: 10.1055/s-2007-994128

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  9 in total

Review 1.  Fetal pharmacotherapy.

Authors:  Gideon Koren; Gil Klinger; Arne Ohlsson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Diagnosis and management of heart failure in the fetus.

Authors:  B Davey; A Szwast; J Rychik
Journal:  Minerva Pediatr       Date:  2012-10       Impact factor: 1.312

3.  Coexistence of ductal constriction and closure of the foramen ovale in utero.

Authors:  H S Kim; S Sohn; M Y Park; J Y Choi
Journal:  Pediatr Cardiol       Date:  2003-07-29       Impact factor: 1.655

4.  Investigation of echocardiographic characteristics and predictors for persistent defects of patent foramen ovale or patent ductus arteriosus in Chinese newborns.

Authors:  Zhen Yuan; Long-Zhen Zhang; Bin Li; Hung-Tao Chung; Jin-Xin Jiang; John Y Chiang; Hsin-Ju Chiang; Hon-Kan Yip; Pei-Hsun Sung
Journal:  Biomed J       Date:  2021-04-15       Impact factor: 4.910

5.  Co-existence of patent ductus arteriosus and left brachiocephalic artery: a case report.

Authors:  Mange Manyama; Erick Mazyala; William Mahalu
Journal:  J Cardiothorac Surg       Date:  2015-02-22       Impact factor: 1.637

Review 6.  Management of Patent Ductus Arteriosus in Premature Infants in 2020.

Authors:  Sarah Parkerson; Ranjit Philip; Ajay Talati; Shyam Sathanandam
Journal:  Front Pediatr       Date:  2021-02-11       Impact factor: 3.418

7.  Fetal adverse effects following NSAID or metamizole exposure in the 2nd and 3rd trimester: an evaluation of the German Embryotox cohort.

Authors:  Katarina Dathe; Johanna Frank; Stephanie Padberg; Stefanie Hultzsch; Evelin Beck; Christof Schaefer
Journal:  BMC Pregnancy Childbirth       Date:  2022-08-26       Impact factor: 3.105

Review 8.  Foetal ductus arteriosus constriction unrelated to non-steroidal anti-Inflammatory drugs: a case report and literature review.

Authors:  Giovanna Battistoni; Ramona Montironi; Jacopo Di Giuseppe; Luca Giannella; Giovanni Delli Carpini; Alessandra Baldinelli; Marco Pozzi; Andrea Ciavattini
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

9.  A case of progressive ductal constriction in a fetus.

Authors:  Eun Young Choi; Meihua Li; Chang Won Choi; Kyo Hoon Park; Jung Yun Choi
Journal:  Korean Circ J       Date:  2013-11-30       Impact factor: 3.243

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.